SET Domain Bifurcated 1 (SETDB1) Antibody
208€ (20 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
SET Domain Bifurcated 1 (SETDB1) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx004701
tested applications
ELISA, WB
Description
SETDB1 Antibody is a Rabbit Polyclonal antibody against SETDB1. This gene encodes a histone methyltransferase which regulates histone methylation, gene silencing, and transcriptional repression. This gene has been identified as a target for treatment in Huntington Disease, given that gene silencing and transcription dysfunction likely play a role in the disease pathogenesis. Alternatively spliced transcript variants of this gene have been described.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | SET Domain Bifurcated 1 (SETDB1) |
| Host | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Recommended Dilution | ELISA: 1 µg/ml, WB: 1/500 - 1/1000. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Purified by affinity chromatography. |
| Size 1 | 20 µl |
| Size 2 | 100 µl |
| Size 3 | 2 × 100 µl |
| Form | Liquid |
| Tested Applications | ELISA, WB |
| Buffer | PBS, pH 7.3, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q15047 |
| Gene ID | 9869 |
| NCBI Accession | NP_001230420.1 |
| Background | Antibody anti-SETDB1 |
| Status | RUO |
| Note | Concentration: 2.52 mg/ml - |
Descripción
Related Products
Human SETDB1 (Histone-lysine N-methyltransferase SETDB1) ELISA Kit
Ver Producto
SETDB1 antibody
This gene encodes a histone methyltransferase which regulates histone methylation, gene silencing, and transcriptional repression. This gene has been identified as a target for treatment in Huntington Disease, given that gene silencing and transcription dysfunction likely play a role in the disease pathogenesis. Alternatively spliced transcript variants of this gene have been described.
Ver Producto